Table 1 CAR-T cell products, trials and articles used for the analysis of toxicities

From: The biological basis and clinical symptoms of CAR-T therapy-associated toxicites

Trial name

Patients (n)

Construct name, CAR-T design

Sponsor

Condition

Reference, comment

ZUMA-1 NCT02348216

101

KTE019, Axicabtagene Ciloleucela, CD28

FMC63 (scFv)

Kite Pharma

NHL

2,27b

 

NCT01865617

29

JCART014, 4-1BB, defined CD4+:CD8+ cell ratio

 

Juno Therapeutics

ALL

11

28,61,95; Careful analysis of CRS, CRES and infections on the mixed population (133 patients)

 

24

  

Juno Therapeutics

CLL

78

 28,61,95; Careful analysis of CRS, CRES and infections on the mixed population (133 patients)

NCT01865617

32

  

Juno Therapeutics

NHL

79

 28,61,95; Careful analysis of CRS, CRES and infections on the mixed population (133 patients)

NCT01626495 NCT01029366

30, phase I

CTL019, Tisagenlecleucela, 4-1BB

 

Novartis

ALL

9

 

ELIANA NCT02435849

75, phase II

    

1,26b

 

NCT01044069

51, phase I

JCART015, CD28

SJ25C1 (scFv)

Juno Therapeutics

ALL

74,75; No grade 5 neurotoxicity observed

ROCKET NCT02535364

38, phase II

   

ALL

96,97; Product development was terminated due to fatal neurotoxicity (5 deaths, cerebral edema)

  1. aFDA-approved drugs
  2. bThe article reporting the trial results and the FDA report necessary for drug approval
Back to article page